Semaglutide

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist FDA-approved for type 2 diabetes management (as Ozempic injectable or Rybelsus oral) and chronic weight management (as Wegovy injectable or oral). In December 2025, oral Wegovy became the first oral GLP-1 approved for weight management, offering a 25mg daily tablet option alongside the established injectable. With over 17,000 participants in clinical trials, semaglutide demonstrates significant weight loss potential (average 15-20% body weight reduction) through appetite suppression, slowed gastric emptying, and enhanced glucose control.

• FDA-Approved Weight Management
• Sustained Appetite Control
• Long-Term Weight Maintenance

FDA-approved treatment with established efficacy for weight loss (15-20% average) and diabetes management. Convenient once-weekly dosing with proven cardiovascular benefits and comprehensive safety data from extensive clinical trials.

Subcutaneous semaglutide mimics native GLP-1, binding to GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through hypothalamic pathways. The 7-day half-life allows weekly dosing.

Peak plasma concentration: 1 day. Elimination half-life: 7 days. Largely cleared by: ~35 days.

Research protocols from published literature — not dosing recommendations.

• Insulin — Monitor Combination: May increase risk of hypoglycemia when combined with insulin; requires blood glucose monitoring and potential insulin dose adjustment
• Tirzepatide — Avoid Combination: Both are incretin mimetics with overlapping mechanisms; concurrent use increases side effects without additional benefit
• Retatrutide — Avoid Combination: Both act on the GLP-1 receptor. Combining them stacks effects on the same receptor pathway, increasing risk of severe nausea, gastroparesis, and hypoglycemia. No published safety data exists for this combination at any dose. If using both under clinical supervision, dose reductions and close monitoring are required.
• Cagrilintide — Synergistic: Combined as CagriSema in clinical trials - amylin analog (cagrilintide) + GLP-1 agonist (semaglutide) for enhanced weight loss
• Metformin — Compatible: Commonly used together for diabetes management; complementary mechanisms with good safety profile
• Growth Hormone Peptides — Compatible: No known interactions; different mechanisms of action and receptor targets
• BPC-157 — Compatible: No contraindications; BPC-157 may help with GI side effects if they occur
• Sulfonylureas — Monitor Combination: Increased hypoglycemia risk; may require sulfonylurea dose reduction when initiating semaglutide
• Oral Medications — Requires Timing: Delayed gastric emptying may affect absorption of oral medications; consider timing adjustments

Supplies:

• Semaglutide pre-filled pen or vial
• Pen needles (if using pen device)
• Alcohol swabs
• Sharps disposal container
• Injection site rotation chart

1. 1If using pre-filled pen, attach new needle and prime according to instructions
2. 2If using vial, draw prescribed dose with appropriate syringe
3. 3Clean injection site with alcohol swab and let dry
4. 4Inject subcutaneously at 90-degree angle (45-degree if lean)
5. 5Hold for 6 seconds after injection to ensure full dose delivery
6. 6Dispose of needle safely and rotate injection sites weekly

Week 1-4: Mild appetite reduction, possible nausea during initial dose. Month 2-3: Noticeable weight loss (5-10% typical), improved satiety. Month 4-6: Continued weight loss (10-15% common), stable glucose levels. Month 6+: Weight loss plateau possible, focus on maintenance. Diabetes benefits: Blood sugar improvements within 1-2 weeks. Long-term: Sustained benefits with continued use.

FDA-approved medication with extensive safety data from trials of 17,000+ participants. Start low and titrate slowly to minimize GI side effects. Most common side effects: nausea, diarrhea, vomiting, constipation, stomach pain, headache, fatigue, dizziness, bloating, belching, gas, heartburn, and upset stomach. Hair loss and changes in skin sensations have been reported. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). May cause thyroid tumors including cancer — tell your provider about neck lumps, hoarseness, trouble swallowing, or shortness of breath. May cause gallbladder problems including gallstones — some may require surgery. Can increase heart rate at rest — tell your provider if you feel your heart racing or pounding for several minutes. Increased risk of low blood sugar (hypoglycemia) when combined with insulin or sulfonylureas. Dehydration from GI side effects may lead to kidney problems — stay well hydrated. Tell all healthcare providers you take Wegovy before any surgery or procedure using anesthesia due to aspiration risk. Stop use 2 months before a planned pregnancy — may harm an unborn baby. Not recommended during pregnancy or breastfeeding.

FDA-approved medication with extensive safety data from trials of 17,000+ participants. Start low and titrate slowly to minimize GI side effects. Most common side effects: nausea, diarrhea, vomiting, constipation, stomach pain, headache, fatigue, dizziness, bloating, belching, gas, heartburn, and upset stomach. Hair loss and changes in skin sensations have been reported. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). May cause thyroid tumors including cancer — tell your provider about neck lumps, hoarseness, trouble swallowing, or shortness of breath. May cause gallbladder problems including gallstones — some may require surgery. Can increase heart rate at rest — tell your provider if you feel your heart racing or pounding for several minutes. Increased risk of low blood sugar (hypoglycemia) when combined with insulin or sulfonylureas. Dehydration from GI side effects may lead to kidney problems — stay well hydrated. Tell all healthcare providers you take Wegovy before any surgery or procedure using anesthesia due to aspiration risk. Stop use 2 months before a planned pregnancy — may harm an unborn baby. Not recommended during pregnancy or breastfeeding.

Semaglutide should be stored at Refrigerate before first use, then refrigerate or room temp up to 28 days.